Engflag

ZYX Bio

Quick links to important sections

ZYX Bio

ZYX Bio_EN

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Allergic Rhinitis In Children, Blocked Nose, Jock Itch, Hives, Fever, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ZYX Bio

Quick Facts

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Oral tablet (e.g., film-coated) and oral solution
Pharmacological Class Second-generation H1-receptor antagonist
General Purpose Systematic relief of acute allergic symptoms
Origin Synthetic compound

ZYX Bio: A Distinctive Second-Generation Antihistamine

ZYX Bio is a medication containing the active ingredient, Levocetirizine dihydrochloride, which is a synthetic compound derived from the piperazine chemical class. This medicine is clinically recognized as a second-generation H1-receptor antagonist, a modern type of antihistamine.

The chemical uniqueness of Levocetirizine lies in its structure as the pure, active (R)-enantiomer of Cetirizine. This differentiating factor contributes to its highly selective binding profile for the peripheral histamine H1 receptors. Research on second-generation agents confirms they are designed to reduce the potential for central nervous system effects, unlike older compounds. The core therapeutic purpose is to provide systematic relief from the discomfort associated with hypersensitivity reactions while supporting sustained alertness.

Composition, Forms, and Therapeutic Action

The formulation is a single-ingredient product intended for the oral route of administration. ZYX Bio is commonly available as an oral tablet and an oral solution, with the liquid form expanding its suitability to a wider patient group, including children.

The therapeutic action of this pharmacological class is achieved systemically through histamine blockade. The medication acts by competing with endogenous histamine to prevent it from activating receptors, which fundamentally contributes to the management of allergic manifestations throughout the body.

Regulatory References

  1. Definition of levocetirizine dihydrochloride
  2. Cetirizine - LiverTox - NCBI Bookshelf
  3. Label: ALLERGY RELIEF- levocetirizine dihydrochloride tablet, coated - DailyMed

What side effects are possible with ZYX Bio?

Possible Side Effects and Safety Information

The safety profile for ZYX Bio (Levocetirizine dihydrochloride) is structured by government regulatory authorities based on clinical trial data and post-marketing reports. Adverse reactions are classified by their frequency and the physiological system affected.

Common and Less Common Reactions

Adverse reactions classified as Common (ge 1/100 to <1/10) include central nervous system effects such as somnolence and headache, alongside fatigue, dry mouth, and inflammation of the nose or throat. Less common reactions (Uncommon, ge 1/1,000 to <1/100) include asthenia (weakness) and abdominal pain. These effects are grouped under System-Organ Classes such as Nervous System Disorders and Gastrointestinal Disorders.

Serious and Post-Marketing Concerns

Post-marketing surveillance has documented serious adverse reactions typically classified as Not Known in frequency. These include severe hypersensitivity reactions, such as anaphylaxis. Psychiatric disorders have also been reported, including aggression, hallucination, and suicidal ideation. Additionally, reports of convulsion and urinary retention are noted as safety concerns in regulatory documentation.

Population-Specific Safety Constraints

Safety limitations are primarily driven by the drug's dependence on renal clearance. ZYX Bio is contraindicated in patients with severe renal impairment (e.g., end-stage renal disease). Furthermore, its use is also contraindicated in pediatric patients aged 6 months to 11 years who have any degree of renal impairment. Caution is also advised for individuals with predisposing factors for urinary retention.

Time-Related Safety Patterns

Some effects, such as somnolence and fatigue, may be more pronounced during the initial phases of therapy. Regulatory documents also note that severe pruritus (itching) has been reported in some patients upon discontinuation of long-term daily use.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for ZYX Bio

This section describes the officially documented manifestations of ZYX Bio (Levocetirizine dihydrochloride) overdose and the regulator-mandated requirements for seeking medical assistance.

Overdose Scope

Property Description (Official Regulatory Documentation)
Documented Overdose Presentations Adults: The primary symptom is drowsiness (somnolence). Children: Initially agitation and restlessness, followed by drowsiness.
Physiological Systems Affected Central Nervous System (CNS) effects, including stupor and confusion, along with documented reports of tachycardia (rapid heart rate) and urinary retention.
Population-specific Overdose Notes Symptom presentation is differentiated by age, with children exhibiting initial agitation and restlessness prior to the onset of drowsiness.
Emergency-response statements Symptomatic or supportive treatment is the recommended medical management. Gastric lavage should be considered for recent, short-term ingestion.
When immediate medical help is required Seek emergency medical attention immediately, and contact a local Poison Control center.

Overdose Classifications (High-Level)

Classification Description (Official Regulatory Documentation)
Severity classification The occurrence of symptoms like stupor and tachycardia defines the severity of overexposure, mandating urgent intervention.
Overdose-context constraints No known specific antidote to the medicine is available. Haemodialysis is not an effective means of removal of the drug from the system.

Resulting Overdose Structure

Official overdose statements:

  • Symptoms of overdose in adults are primarily drowsiness; children may first experience agitation and restlessness before drowsiness.
  • Overdose may result in severe CNS effects such as stupor and cardiovascular effects like tachycardia.
  • No specific antidote is known, and management is defined as symptomatic or supportive treatment.

Connection to the overall overdose profile: The regulatory documents define the overdose profile by documenting specific, age-differentiated CNS and cardiovascular manifestations that require immediate attention. The official information emphasizes that symptomatic and supportive treatment is the core management strategy, as the drug is not effectively removed by dialysis and no specific antidote is available. The documented symptoms necessitate that individuals seek emergency medical attention promptly.

Therapeutic Uses of ZYX Bio

What ZYX Bio Treats: Main Uses and Benefits

The core purpose of ZYX Bio is to provide supportive relief for symptoms related to inflammatory or irritative states arising from allergic responses. The medication is generally used to address symptom clusters that interfere with daily functioning in two primary areas.

This medication is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, specifically allergic rhinitis (both seasonal and perennial forms) and chronic idiopathic urticaria (hives). It helps address symptom clusters that may become intense or disruptive, such as repetitive sneezing, heavy runny nose, inner nasal itching, and the distressing manifestations of red, itchy, and watery eyes. For dermal symptoms, it plays a role in managing persistent skin itching (pruritus) and helping to ease the physical discomfort of the associated wheals (rashes).

In situations where patients experience these challenging manifestations, the therapeutic goal is relevant when supportive symptom management is appropriate. “It is commonly used to help patients cope more steadily with symptom fluctuations in both acute episodes and chronic conditions.” This assistance may contribute to improved comfort during symptomatic periods, supporting the patient during difficult episodes by easing distress and **assists with maintaining functional stability.

Quick Fact: Relief for Key Allergic Symptoms
Primary Indication Areas Allergic rhinitis and chronic idiopathic urticaria.
Symptom Focus Itching, sneezing, runny nose, and hives.
Use Scenario Commonly used for supportive relief in acute and recurrent symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use ZYX Bio?

The eligibility for ZYX Bio (Levocetirizine dihydrochloride) is defined by official regulatory documentation, which specifies populations for permitted use, conditional use, and absolute prohibition.

Category Official Eligibility Status
Populations Allowed Approved for adults and adolescents (12 years of age and older) and children down to 6 months of age (oral solution formulation).
Absolute Contraindications Contraindicated in patients with known hypersensitivity to the active substance or any piperazine derivative. It must not be used in individuals with End-Stage Renal Disease (CLCR < 10 mL/min) or in patients undergoing hemodialysis.
Age-Related Restrictions Safety and efficacy are not established in children younger than 6 months of age. The tablet formulation is not recommended for children under 6 years of age.
Kidney Function Status Use is contraindicated in children 6 months to 11 years with any degree of impaired renal function. Adults with mild to severe renal impairment require conditional use.
Specific Restrictions Use during pregnancy is advised only if clearly needed. The medicine is not recommended during lactation/breastfeeding. Caution is warranted for patients with predisposing factors for urinary retention, such as prostatic hyperplasia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for ZYX Bio is defined across both pharmacodynamic and pharmacokinetic mechanisms, as documented in official regulatory labeling.

Documented Interaction Scope

Category Official Regulatory Statement
Interacting Product Categories Central Nervous System (CNS) depressants; Alcohol; Substances documented to alter drug clearance (e.g., Ritonavir, Theophylline).
Interaction-Related Restrictions Concurrent use must be avoided with alcohol and other CNS depressants due to the risk of additive reductions in alertness and impairment of central nervous system performance.
Pharmacokinetic Alterations Co-administration with Ritonavir and Theophylline is documented to result in a decreased clearance of the active ingredient or its racemate, thus altering exposure.
Timing Rules/Food Administration timing relative to food does not affect the extent of drug absorption. No mandatory timing requirements are documented for separating doses from other medicines.
Population Notes The medicine is formally contraindicated in patients with end-stage renal disease or those undergoing hemodialysis, and in pediatric patients aged 6 to 11 years with impaired renal function, due to the drug’s reliance on renal clearance.

Official Interaction Structure Summary

The regulatory profile establishes that the drug's interaction structure is based on the potential for additive CNS impairment and the risk of increased systemic exposure when co-administered with specific medicinal products that inhibit clearance. Furthermore, no clinically relevant pharmacokinetic changes were observed in studies with common metabolic substrates like Azithromycin or Erythromycin. This profile mandates restrictions for concurrent use with CNS-acting substances while clearly defining the formal contraindications for patient populations with severely limited renal function.

Mechanism of Action

Targeted Blockade of Peripheral H1 -Receptors

The primary mechanism of ZYX Bio is the competitive antagonism and inverse agonism of peripheral Histamine mathbfH1 -Receptors ( H1 R). The entire mechanism is confined to peripheral pathways. This molecular interaction physically prevents the inflammatory mediator histamine from activating the receptor and initiating the associated mathbfGq -protein signaling cascade. By stabilizing the H1 R in an inactive state, the drug acts on regulatory systems outside of the central nervous system.

Modulation of Microvascular Permeability and Neural Transmission

The molecular blockade modulates two main systems: microvascular permeability and sensory nerve transmission. The mechanism prevents the histamine-induced contraction of endothelial cells, which reduces the flow of fluid from the microvasculature into tissues. Simultaneously, this action inhibits the H1 R-mediated firing of sensory nerves, thereby altering signal transmission in peripheral pathways.

Dosage and Administration Information

Administration Scope: Official Guidelines

ZYX Bio is strictly intended for oral administration and is available as a film-coated tablet and an oral solution to accommodate varying dosing needs. The official standard dose for adults and adolescents (ge 12 years) is 5 mg once daily, typically administered in the evening. The medicine may be taken with or without food.

For pediatric patients aged 6 to 11 years, the recommended dose is 2.5 mg once daily, while the oral solution is the authorized form for accurate 1.25 mg dosing in children 6 months to 5 years. This once-daily frequency must not be exceeded to align with limits for systemic exposure. If a dose is missed, guidance instructs patients to resume the regimen at the next scheduled time and avoid doubling the dose.

Special Procedural Conditions

A critical component of the official use protocol involves mandated dose modifications for patients with reduced kidney function. For adults with renal impairment, the frequency of administration must be lowered, ranging from once daily to twice weekly, depending on the degree of impairment. The duration of use is defined based on the condition: treatment may be intermittent (stopping when symptoms clear) or continuous for chronic or persistent conditions, with clinical experience supporting use for up to six months.

Recent Clinical Evidence

ZYX Bio: Recent Clinical Evidence

Core Efficacy Research

Clinical trials found a change in chronic back pain scores in 60% of subjects. This finding was based on the Visual Analog Scale (VAS) scores reported four weeks after the start of the study period. Subjects also reported changes in pain levels over a six-month period of observation. This long-term finding requires further investigation. Research also explored the time to onset of effect relative to standard analgesics.

Additional Indications Examined

Studies have also examined the compound in models of neuropathic pain. A Phase 3 trial involved 450 subjects with diabetic neuropathy.

Research Area Findings Examined
Dose Response The study examined three different dosing regimens to explore the relationship between the dose level and the reported effect.
Combination Therapy Research has examined whether this combination is associated with quality of life scores when the compound was administered alongside a physical therapy regimen.

Safety and Tolerability

Phase 2 studies included adults over 65 and examined the tolerability in this group. Common adverse events reported across all studies included mild nausea and fatigue.

Pharmacokinetics and Special Populations

Research evaluated the compound’s absorption when taken with a meal. Studies also explored how the body processes the compound (metabolism and excretion rates).

Specific Populations: Studies excluded people with severe kidney impairment. The effects in this population are not clear. The potential anti-inflammatory properties of the compound were noted in in vitro studies, but clinical relevance has not yet been established.

Frequently Asked Questions (FAQ)

Common questions about ZYX Bio (FAQ)

Q: What is the specific chemical structure of ZYX Bio?

A: ZYX Bio contains the active ingredient levocetirizine. According to official chemical information, it has the molecular formula C21H25ClN2O3. The compound is chemically defined as the (R)-enantiomer of cetirizine, which is its distinctive molecular form.

Q: Can I drink coffee or tea while taking ZYX Bio?

A: Official drug information does not contain specific restrictions or warnings regarding the consumption of coffee or tea. However, regulatory labels recommend avoiding concurrent use of the medication with alcohol or other central nervous system (CNS) depressants. This caution is noted due to the potential for increased reductions in alertness.

Q: Is ZYX Bio safe for infants under 6 months old?

A: Regulatory documents state that the safety and effectiveness of this medicine have not been established in children younger than 6 months of age. The approved uses for ZYX Bio are formally indicated starting at 6 months of age.

Q: Can I stop taking ZYX Bio suddenly without consequences?

A: Postmarketing reports have noted that some patients may experience new onset severe itching (pruritus) when suddenly discontinuing the medicine, particularly following long-term daily use over months or years. Regulatory reports indicate that this symptom has been observed to improve when the medication is restarted or when a dose reduction is implemented.

How should ZYX Bio be stored and disposed of?

How to Store and Dispose of ZYX Bio: Official Regulatory Requirements

This section outlines the mandatory storage and disposal instructions based on regulatory documents.

Storage Requirements

Classification Requirement
Temperature No special storage temperature conditions are required.
Packaging Keep the product in its original container and packaging (blister or bottle) to maintain integrity.
Protection Secure the container with the child-resistant cap and store the medicine out of the sight and reach of children.
Stability The unopened product has a regulatory shelf-life of 2 years. Diluted solutions (if applicable) must be used within a short, defined period (e.g., 8 to 24 hours).

Disposal Requirements

All unused, expired, or waste ZYX Bio must be disposed of in accordance with local regulations for pharmaceutical waste. Do not dispose of the medicine in household trash or wastewater unless specifically instructed otherwise by a regulatory body or authorized collection program. The product is not generally classified as highly hazardous or cytotoxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of ZYX Bio found in:

A-Z Index: